Abstract
This article briefly summarizes clinically relevant new aspects of the recently published German, Austrian, and Swiss Onkopedia guideline for the treatment of locally advanced rectal cancer. Main aspects comprise (i) the use of total neoadjuvant therapy for rectal cancers with high-risk features, (ii) treatment with neoadjuvant chemotherapy for patients with a low risk for local recurrence, (iii) immunotherapy using dostarlimab in patients with MSI high/dMMR rectal cancer, as well as (iv) the implementation of organ sparing treatment concepts. The availability of several evidence-based treatment options requires intensive discussion within the multidisciplinary team as well as dedicated information for patients about treatment goals, options, and risks of individual treatment approaches.
| Original language | English |
|---|---|
| Journal | Oncology Research and Treatment |
| Volume | 47 |
| Issue number | 12 |
| Pages (from-to) | 610-615 |
| Number of pages | 6 |
| ISSN | 2296-5270 |
| DOIs | |
| Publication status | Published - 2024 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Research Areas and Centers
- Research Area: Center for Population Medicine and Public Health (ZBV)
Fingerprint
Dive into the research topics of 'Guidelines of Onkopedia: What Is New? Locally Advanced Rectal Cancer'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver